Navigation Links
Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix Medical Corporation (OTC BB: CONX) and the Company's clinical collaborators reported new clinical data demonstrating a significant correlation between serum levels of the Company's patented AtherOx(TM) bio-markers and cardiovascular disease. The data was presented at the XXIst Congress of the International Society on Thrombosis and Hemostasis (ISTH) in Geneva, Switzerland.

Data released this week shows the association of antibodies to the AtherOx complex (anti-AtherOx) with vascular thrombosis (particularly with arterial thrombosis) in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and anti-phospholipid syndrome. The study looked at 113 SLE patients (94 with secondary anti-phospholipid syndrome and 19 without) and concluded the measurement of anti-AtherOx is significantly better than conventional anti-cardiolipin testing in identifying patients with vascular complications, and suggests the pivotal role of B2GPI in vascular injury and thrombosis.

As with SLE, patients with diabetes also develop significant vascular complications such as atherosclerotic cardiovascular disease. Data from an additional study also released indicated increased levels of the AtherOx complex in patients with diabetes mellitus. This study of 50 Type 2 diabetic patients taking cholesterol-lowering statin drugs (Lipitor(R), Crestor(R) and Zocor(R)) showed reduced levels of AtherOx complexes, suggesting that these statins may also have a beneficial effect in lowering oxidative stress, a significant factor in atherosclerosis.

An interim report was released on a third ongoing prospective study of anti-phospholipid antibodies and AtherOx in patients with coronary artery disease (the CaPS study). While both anti-phospholipid antibodies and AtherOx complexes are present in patients with coronary artery disease, data on 232 patients tested to date showed
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... clinical studies evaluating potential new medicines in the ... upcoming 2014 European Society of Medical Oncology (ESMO) ... Spain . Data being presented include results ... and efficacy of veliparib (ABT-888), a poly (adenosine ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... SILVER SPRING, Md., March 25, 2011 The U.S. Food ... patients with late-stage (metastatic) melanoma, the most dangerous type ... ) Melanoma is the leading cause ... cases of melanoma were diagnosed in the United States ...
... CoreLab Partners, Inc , the global entity resulting ... is set to attend and actively participate in several ... two weeks. "The legacy of our organization ... physicians, scientists and operational personnel have provided to the ...
Cached Medicine Technology:FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 2FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 3CoreLab Partners Collaborates at Worldwide Industry Conferences 2
(Date:9/22/2014)... 2014 PreDiabetes Centers , a ... with companies to help employees learn their risk for ... as part of a collaboration with the American Diabetes ... , PreDiabetes Centers Medical Director Alan Hopkins, MD, ... Austin on Tuesday, October 21st to discuss the epidemic ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... have known that bacterial pneumonia can raise your risk of ... actually invade and kill heart cells, increasing the chances of ... scientists report. In mice, monkeys and human heart ... the bacteria, and they tried a vaccine that might one ...
(Date:9/22/2014)... 2014 At the 10th Clinton ... Nutrition Partnership (SNP) announced the successful launch of ... Cardiovascular Risk Reduction Program for Women. The announcement ... mitigate their risk of heart disease through a ... plan for addressing significant global challenges made by ...
(Date:9/22/2014)... 2014 TweetMyJobs, a global ... today an agreement with HealthcareSource, the leading ... healthcare industry. The agreement gives HealthcareSource clients ... recruiting solutions directly from within HealthcareSource Position ... healthcare organizations. The partnership provides TweetMyJobs additional ...
(Date:9/22/2014)... MAINE AND BOSTON -- In a collaboration that ... advance cancer research and patient care and accelerate ... Beth Israel Deaconess Medical Center (BIDMC) have established ... institutions, presidents announced today. , A recently signed ... Center to establish a comprehensive relationship in the ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
... could help prevent complications for pregnant women with the ... the 20th week of pregnancy and is characterized by ... the urine. In severe cases it can lead to ... the mother to suffer a series of potentially fatal ...
... embryo transfer instead of a double embryo transfer during ... births without substantially lowering live births, // according to ... than 36 and compared the two approaches of in ... at least one live birth and rates of multiple ...
... nearly 15 million people worldwide. Problems with a ... sneezing, laughing, or lifting heavy objects. Austrian researchers ... with their own stem cells, which they say ... involves removing stem cells from a patient's arm, ...
... that stem cell therapy is effective in treating pigs ... cells from one pig's bone marrow and injecting them ... heart's function to its original condition. ,Researchers studied ... and half of them received therapy. They found injecting ...
... According to a recent study researchers say autistic boys with ... suffering from a language-related disorder known as Specific Language Impairment ... specialists better understand autism and how to choose the best ... MRI scans to look at Broca’s area -- a key ...
... new study the healthiest environment for your child at bedtime ... at night may put children at risk for leukemia.// ... night workers and an increased risk for breast cancer, further ... factor for leukemia. ,Researchers have determined that light at ...
Cached Medicine News:
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Medicine Products: